India faces a challenging global economic outlook for 2026-27. Geopolitical tensions and volatile oil prices are key concerns. However, Ind...

The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...

India Pharma Conference: India is set to become a global leader in advanced medicines like biologics and biosimilars, Union Minister J P Na...

Markets surged for the fourth consecutive session, buoyed by favorable geopolitical cues. Key stocks like TCS, HDFC Bank, ITC Hotels, Hyund...

India's Biotechnology Industry Research Assistance Council, BIRAC, marked its 14th Foundation Day. It has significantly boosted India's bio...

The Union Budget is making a significant investment in India's health and innovation. Biopharma has been identified as a key strategic sect...

The Union Budget 2026-27 focuses on fortifying the Indian economy against global volatility through strategic investments in technology, he...

India's biopharmaceutical sector receives a significant boost with the Union Budget's ₹10,000 crore Biopharma SHAKTI programme. This initia...

Union Budget 2026: With the announcement of the 'Biopharma Shakti' initiative, India is gearing up to take the world stage in biopharmaceut...

Union Budget 2026: Finance Minister Nirmala Sitharaman has presented a six-point plan to boost India's economy. The strategy prioritizes ma...

In 2024, India's biopharma sector marked notable achievements, with approvals of key biosimilars and the launch of advanced CAR-T therapy. ...

The joint report by the USA India Chamber of Commerce & PwC India titled, “Clinical Trial opportunities in India” which will be released at...

NITI Aayog CEO Amitabh Kant, Pfizer CEO Dr Alberta Bourla, National Institutes of Health (NIH) Director Dr Francis Collins and Food and Dru...

India's intellectual property regulations and liabilities laws pose a major barrier to foreign companies, specially from the US, that preve...

India's health and innovative and biopharma sector deserves better attention from the government to help realise its full potential

Noting that India has the ability to be a "global hub" in the bio-pharma and healthcare sector, industry leaders have said that steps need ...

India's bio-pharma sector may see a surge in R&D spending to about $25 billion in the next 15 years, according to a Boston Consulting Group...